ReviewPediatric nephrology (Berlin, Germany)2021
2020 update on the renin-angiotensin-aldosterone system in pediatric kidney disease and its interactions with coronavirus.
Review in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.Metabolites · 2026Article
- The Role of Renin-Angiotensin System in Diabetic Nephropathy: An Update.Mini reviews in medicinal chemistry · 2025Review
- Post-COVID Hypertension With Hyperreninemic Hyperaldosteronism in a Pediatric Patient.Clinical case reports · 2025Article
- Ang-(1-7) attenuates podocyte injury induced by high glucoseArchives of endocrinology and metabolism · 2023Article
- How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review.Open access emergency medicine : OAEM · 2023Review
- The roles of gut microbiota and its metabolites in diabetic nephropathy.Frontiers in microbiology · 2023Review
- Renoprotective Effects of Luteolin: Therapeutic Potential for COVID-19-Associated Acute Kidney Injuries.Biomolecules · 2022Review
- Acute kidney injury in pediatrics: an overview focusing on pathophysiology.Pediatric nephrology (Berlin, Germany) · 2022Review
- Kidney implications of SARS-CoV2 infection in children.Pediatric nephrology (Berlin, Germany) · 2022Review
- Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus.Pediatric nephrology (Berlin, Germany) · 2022Review
- Evaluation of Active Renin Concentration in A Cohort of Adolescents with Primary Hypertension.International journal of environmental research and public health · 2022Article
- A narrative review of Hyporeninemic hypertension-an indicator for monogenic forms of hypertension.Pediatric medicine (Hong Kong, China) · 2022Article
- Catechins: Therapeutic Perspectives in COVID-19-Associated Acute Kidney Injury.Molecules (Basel, Switzerland) · 2021Review
- How SARS-CoV-2 might affect potassium balance via impairing epithelial sodium channels?Molecular biology reports · 2021Review
- CKD patients: A high-risk category for severe COVID-19.Journal of medical virology · 2021Article
- Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.Journal of medical virology · 2021Article
- Molecularly imprinted spongy columns for Angiotensin(II) recognition from human serum.Biotechnology progress · 2021Article
- Effect of furosemide on comprehensive renin-angiotensin-aldosterone system activity of Thoroughbred horses.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The last decade was crucial for our understanding of the renin-angiotensin-aldosterone system (RAAS) as a two-axis, counter-regulatory system, divided into the classical axis, formed by angiotensin-converting enzyme (ACE), angiotensin II (Ang II), and the angiotensin type 1 receptor (AT1R), and the alternative axis comprising angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) (Ang-(1-7)), and the Mas receptor. Breakthrough discoveries also took place, with other RAAS endopeptides being described, including alamandine and angiotensin A. In this review, we characterize the two RAAS axes and the role of their components in pediatric kidney diseases, including childhood hypertension (HTN), pediatric glomerular diseases, congenital abnormalities of the kidney and urinary tract (CAKUT), and chronic kidney disease (CKD). We also present recent findings on potential interactions between the novel coronavirus, SARS-CoV-2, and components of the RAAS, as well as potential implications of coronavirus disease 2019 (COVID-19) for pediatric kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.